Advertising

NASDAQ:CELG

108.24
0.00 (0.00%) 1d
0
Showing 1 to 15 of 90 entries
PAST TOP PICK

(A Top Pick Dec 03/18, Up 47%) Celgene had made a number of mis-steps, including management applying for multiple FDA approvals. One thing he really liked about the acquisition was the price it was bought. The acquisition by BMY helped them diversify and it seems to be going well.

Consumer Products
SELL
He sold out because it's going to be merged with Bristol Myers, they received full value, and there's always deal risk. Celgene owners may get a premium if 3 drugs come to market and exceeded certain thresholds. This is a side bet, and not the way he likes to invest.
Consumer Products
PAST TOP PICK

(A Top Pick Oct 22/18, Up 25%) The Bristol acquisition was perfect. CELG boasts strong competitive barriers to their products and their product pipeline will pleasantly surprise the market. He's not worried about the US election and the negative effect on US healthcare; in fact, he loves buying stocks when others fear or hate them.

Consumer Products
COMMENT

He started buying BMY-N ahead of the merger discussions with CELG-Q. If the merger fails, holding the buyer is safer as arbitragers unwind hedges. The combined company would be a good cash flow generator, which would help internal growth and debt pay down.

Consumer Products
DON'T BUY

Heading into the election cycle, pharma will be under pressure. He prefers being into medical devices. He has a hard time being excited about either CELG or BMY, especially if the market is currently jittery. (Analysts’ price target is $100.33)

Consumer Products
PAST TOP PICK
(A Top Pick Mar 21/18, Up 10%) Sold it because it's getting taken out by Bristol Myers.
Consumer Products
BUY
Bistol-Myers bought it which is good news for Celgene holders.
Consumer Products
PAST TOP PICK
(A Top Pick May 30/18, Up 22%) They have a lot of new products in their patent portfolio. They are being acquired. It would be a nice speculative holding in the marketplace when it closes.
Consumer Products
PAST TOP PICK
(A Top Pick Mar 20/18, Down 0.2%) It was one of his hopes in the medical area for great growth. They are being acquired. He is going to keep holding it.
Consumer Products
SELL
Having issues in terms of competition. They wanted to merge with Bristol. She doesn't think the combination makes it a better company. She would sell on the announcement (as the stock lifted).
Consumer Products
BUY
It has a better growth pipeline. Biotech in the US is probably one of the better areas of growth. He prefers the IBB-Q ETF. He likes the sector. There is good growth potential.
Consumer Products
TOP PICK
They're in oncology, particularly blood cancer. They've had some headwinds in some FDA submissions due to mistakes by management. So, the stock got punished. It's trading at 6.5x and generating a ton of cash flow as good test results come in. They are diversifying as they acquire. Hoeps investor sentiment improves. (Analysts’ price target is $108.61)
Consumer Products
DON'T BUY
They have drugs going off patent in 2020. They have 5 big names coming into trials at the same time. He is not clear on what will cause it to bounce. Don't buy lows. The price is confirmed by relative strength.
Consumer Products
TOP PICK

(no dividend yield, Analysts' price target: not given) A global biotech focussed on cancer. They've stumbled recently, but phase 3 trials have been positive. Their drugs have a diminished chance of going generic, according to data. Attractive value. smart managers and a rich pipeline of drugs coming.

Consumer Products
DON'T BUY

They have a good cash float, which will lead to a share buyback, he feels. He sees resistance at $90-$100, which will be tough to battle through. He would suggest taking a loss if you hold this one, because the future capex requirements will be more expensive as interest rates rise. He would prefer IHI-N if you like the healthcare space as he does.

Consumer Products
Showing 1 to 15 of 90 entries

Celgene Corp(CELG-Q) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Celgene Corp is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Celgene Corp(CELG-Q) Frequently Asked Questions

What is Celgene Corp stock symbol?

Celgene Corp is a American stock, trading under the symbol CELG-Q on the NASDAQ (CELG). It is usually referred to as NASDAQ:CELG or CELG-Q

Is Celgene Corp a buy or a sell?

In the last year, there was no coverage of Celgene Corp published on Stockchase.

Is Celgene Corp a good investment or a top pick?

Celgene Corp was recommended as a Top Pick by on . Read the latest stock experts ratings for Celgene Corp.

Why is Celgene Corp stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Celgene Corp worth watching?

0 stock analysts on Stockchase covered Celgene Corp In the last year. It is a trending stock that is worth watching.

What is Celgene Corp stock price?

On 2019-11-20, Celgene Corp (CELG-Q) stock closed at a price of $108.24.